0OIR Alk Upgrades Its Full-year Financial Outlook
August 04 2022 - 7:37AM
UK Regulatory
TIDMALK TIDMB
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that
based on a strong sales momentum and the outlook for the remainder
of the year, ALK has upgraded its full-year outlook. As a
result:
-- Revenue is now expected to grow 10-13% in local currencies (previously:
8-12%).
-- EBITDA is now expected to increase to DKK 675-750 million (previously:
625-725).
ALK will publish its Q2 performance in connection with the
six-month interim report on 11 August 2022.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile
+45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
This information is information that ALK-Abelló A/S is obliged
to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on
allergy and allergic asthma. It markets allergy immunotherapy
treatments and other products and services for people with allergy
and allergy doctors. Headquartered in Hørsholm, Denmark, ALK
employs around 2,600 people worldwide and is listed on Nasdaq
Copenhagen. Find more information at www.alk.net.
Attachment
-- FM_13_22UK_04082022
https://ml-eu.globenewswire.com/Resource/Download/d153a6d0-5efc-4acb-9c8d-d2bbaa39eac9
(END) Dow Jones Newswires
August 04, 2022 07:37 ET (11:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Apr 2024 to May 2024
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From May 2023 to May 2024